MAURIZI, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 828
EU - Europa 568
AS - Asia 290
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 1.694
Nazione #
US - Stati Uniti d'America 826
IE - Irlanda 193
SG - Singapore 136
IT - Italia 130
CN - Cina 99
DE - Germania 69
SE - Svezia 63
TR - Turchia 33
UA - Ucraina 33
GB - Regno Unito 31
FI - Finlandia 15
VN - Vietnam 14
CZ - Repubblica Ceca 8
FR - Francia 7
BE - Belgio 5
BR - Brasile 4
IN - India 4
RU - Federazione Russa 4
ES - Italia 3
EU - Europa 3
NL - Olanda 3
AT - Austria 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
CA - Canada 1
IL - Israele 1
MO - Macao, regione amministrativa speciale della Cina 1
PR - Porto Rico 1
TW - Taiwan 1
Totale 1.694
Città #
Chandler 221
Dublin 191
Jacksonville 106
Singapore 105
Boardman 77
Ashburn 34
Ann Arbor 33
New York 31
Lawrence 28
Princeton 28
L'aquila 25
Izmir 23
Wilmington 23
Kitzingen 21
Nanjing 20
L’Aquila 19
Beijing 15
Dong Ket 14
Rome 14
San Mateo 12
Falls Church 11
Nanchang 10
Kunming 9
Milan 9
Shanghai 9
Woodbridge 9
Brno 8
Dallas 8
Bremen 7
Seattle 7
Aquila 6
Dearborn 6
Norwalk 6
West Jordan 6
Helsinki 5
Munich 5
Brussels 4
Cologne 4
Hebei 4
Jiaxing 4
Mountain View 4
Verona 4
Washington 4
Des Moines 3
Fremont 3
Jinan 3
Lappeenranta 3
Los Angeles 3
Moscow 3
Tianjin 3
Amsterdam 2
Bologna 2
Hanover 2
Lanzhou 2
London 2
Manoppello 2
Monserrato 2
Nerviano 2
Ningbo 2
Paganica 2
Pisa 2
Pune 2
Regensburg 2
Shenyang 2
Vienna 2
Zhengzhou 2
Barcelona 1
Boscotrecase 1
Casal di Principe 1
Changsha 1
Chicago 1
Cividate al Piano 1
Cochabamba 1
Cologno Monzese 1
Dubai 1
Edinburgh 1
Fortaleza 1
Friesland 1
Galliate 1
Gandhi Nagar 1
Guiyang 1
Haikou 1
Hangzhou 1
Harbin 1
Houston 1
Ilhabela 1
Istanbul 1
Leipzig 1
Macao 1
Madrid 1
Marília 1
Modena 1
Montreal 1
Mumbai 1
Noisy-le-grand 1
Olinda 1
Pescara 1
Piera 1
Poli 1
Redmond 1
Totale 1.276
Nome #
SMALL INTERFERING RNA (siRNA) PER LA TERAPIA DELL’OSTEOPETROSI AUTOSOMICA DOMINANTE DI TIPO 2 (ADO2) CAUSATA DA MUTAZIONE DEL GENE CLCN7 (ADO2 CLCN7-DIPENDENTE) 143
Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation 103
Anabolic and antiresorptive modulation of bone homeostasis by the epigenetic modulator sulforaphane, a naturally occurring isothiocyanate 87
Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models 81
A COMPLEX ROLE FOR LIPOCALIN 2 IN BONE METABOLISM: GLOBAL ABLATION IN MICE INDUCES OSTEOPENIA CAUSED BY AN ALTERED ENERGY METABOLISM 81
Effective small interfering RNA therapy to treat CLCN7-dependent autosomal dominant osteopetrosis type 2 79
SMALL INTERFERING RNA (siRNA) FOR THE THERAPY OF TYPE 2 (ADO2) AUTOSOMAL DOMINANT OSTEOPETROSIS CAUSED BY CLCN7 (ADO2 CLCN7-DEPENDENT) GENE MUTATION 79
RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development 78
Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone 72
The Great Beauty of the osteoclast 71
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 63
Improvement of the skeletal phenotype in a mouse model of diastrophic dysplasia after postnatal treatment with N-acetylcysteine 57
Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications 55
Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice 55
Anti-osteoblastogenic, pro-inflammatory and pro-angiogenic effect of extracellular vesicles isolated from the human osteosarcoma cell line MNNG/HOS 52
Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications 48
Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry 47
The osteoclast in bone metastasis: Player and target 43
Lipocalin 2 serum levels correlate with age and bone turnover biomarkers in healthy subjects but not in postmenopausal osteoporotic women 43
Osteopetrosis 41
A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders 41
How the "seed" prepares the "soil": The bone/bone marrow pre-metastatic niche 37
Lipocalin 2 Influences Bone and Muscle Phenotype in the MDX Mouse Model of Duchenne Muscular Dystrophy 37
Reprint of: The Great Beauty of the osteoclast 33
MC4R-dependent suppression of appetite by bone-derived lipocalin 2 32
Role of Neural (N)-Cadherin in Breast Cancer Cell Stemness and Dormancy in the Bone Microenvironment 32
Glucose Uptake and Runx2 Synergize to Orchestrate Osteoblast Differentiation and Bone Formation 27
Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta 24
Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) Autosomal Dominant Oosteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation 21
Therapeutic compounds and compositions 12
A mutation in the ZNF687 gene that is responsible for the severe form of Paget's disease of bone causes severely altered bone remodeling and promotes hepatocellular carcinoma onset in a knock-in mouse model 12
Phenotype of the first mouse model of Cole Carpenter Syndrome. 10
Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans 10
Experimental therapies for osteopetrosis 10
A perspective on muscle phenotyping in musculoskeletal research 9
Pre-proenkephalin 1 is Downregulated Under Unloading and is Involved in Osteoblast Biology 9
High Bone Mass Disorders: New Insights From Connecting the Clinic and the Bench 8
Anabolic and antiresorptive modulation of bone homeostasis by the epigenetic modulator sulforaphane, a naturally occurring isothiocyanate 7
Effect of Allele-Specific Clcn7G213R siRNA Delivered Via a Novel Nanocarrier on Bone Phenotypes in ADO2 Mice on 129S Background 5
Editorial: The bone/bone marrow microenvironment: A hub for immune regulation of the tumor cells fate 2
Totale 1.756
Categoria #
all - tutte 9.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.058


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020123 0 0 0 0 3 35 38 0 14 11 4 18
2020/2021169 2 22 1 17 15 7 17 8 24 9 25 22
2021/2022163 7 3 30 10 7 9 6 16 21 9 9 36
2022/2023585 34 42 4 77 49 52 1 54 245 2 24 1
2023/2024229 17 16 16 7 20 60 3 1 6 11 6 66
2024/2025237 24 19 76 63 55 0 0 0 0 0 0 0
Totale 1.756